Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03473756
Title	Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)
Acronym	FORT-2
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Bayer
Indications	urethra transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma
Therapies	Atezolizumab Atezolizumab + Rogaratinib
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| FRA \| ESP \| DEU \| AUT